



<p>Recipient Information</p> <p>1. Recipient Name SCRIPPS RESEARCH INSTITUTE, THE 130 SCRIPPS WAY JUPITER, FL 33458</p> <p>2. Congressional District of Recipient 18</p> <p>3. Payment System Identifier (ID) 1330435954A5</p> <p>4. Employer Identification Number (EIN) 330435954</p> <p>5. Data Universal Numbering System (DUNS) 148230662</p> <p>6. Recipient's Unique Entity Identifier MGUCX773RNJ8</p> <p>7. Project Director or Principal Investigator Mauricio de Aguiar Martins, PHD Assistant Professor mmartins@scripps.edu Redacted by agreement</p> <p>8. Authorized Official Redacted by agreement Redacted@scripps.edu (858) 784-8653</p>	<p>Federal Award Information</p> <p>11. Award Number 5R21AI157929-02</p> <p>12. Unique Federal Award Identification Number (FAIN) R21AI157929</p> <p>13. Statutory Authority 42 USC 241 42 CFR 52</p> <p>14. Federal Award Project Title A nonhuman primate model to study the immunological effects of feminizing hormone therapy in transgender women</p> <p>15. Assistance Listing Number 93.855</p> <p>16. Assistance Listing Program Title Allergy and Infectious Diseases Research</p> <p>17. Award Action Type Non-Competing Continuation</p> <p>18. Is the Award R&D? Yes</p>																										
<p>Federal Agency Information</p> <p>9. Awarding Agency Contact Information PAULA Acevedo Grants Management Specialist NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES paula.acevedo@nih.gov 301-435-2860</p> <p>10. Program Official Contact Information James E. Cummins Program Official NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES cumminsje@niaid.nih.gov 240-292-4800</p>	<table border="1" style="width: 100%;"> <tr> <th colspan="2" style="text-align: center;">Summary Federal Award Financial Information</th> </tr> <tr> <td colspan="2">19. Budget Period Start Date 12/01/2021 – End Date 11/30/2022</td> </tr> <tr> <td>20. Total Amount of Federal Funds Obligated by this Action</td> <td style="text-align: right;">\$205,562</td> </tr> <tr> <td> 20 a. Direct Cost Amount</td> <td style="text-align: right;">\$173,329</td> </tr> <tr> <td> 20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$32,233</td> </tr> <tr> <td>21. Authorized Carryover</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>22. Offset</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>23. Total Amount of Federal Funds Obligated this budget period</td> <td style="text-align: right;">\$205,562</td> </tr> <tr> <td>24. Total Approved Cost Sharing or Matching, where applicable</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>25. Total Federal and Non-Federal Approved this Budget Period</td> <td style="text-align: right;">\$205,562</td> </tr> <tr> <td colspan="2" style="text-align: center;">-----</td> </tr> <tr> <td colspan="2">26. Project Period Start Date 12/01/2020 – End Date 11/30/2022</td> </tr> <tr> <td>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</td> <td style="text-align: right;">\$478,188</td> </tr> </table> <p>28. Authorized Treatment of Program Income Additional Costs</p> <p>29. Grants Management Officer - Signature Nicole A Guidetti</p>	Summary Federal Award Financial Information		19. Budget Period Start Date 12/01/2021 – End Date 11/30/2022		20. Total Amount of Federal Funds Obligated by this Action	\$205,562	20 a. Direct Cost Amount	\$173,329	20 b. Indirect Cost Amount	\$32,233	21. Authorized Carryover	\$0	22. Offset	\$0	23. Total Amount of Federal Funds Obligated this budget period	\$205,562	24. Total Approved Cost Sharing or Matching, where applicable	\$0	25. Total Federal and Non-Federal Approved this Budget Period	\$205,562	-----		26. Project Period Start Date 12/01/2020 – End Date 11/30/2022		27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$478,188
Summary Federal Award Financial Information																											
19. Budget Period Start Date 12/01/2021 – End Date 11/30/2022																											
20. Total Amount of Federal Funds Obligated by this Action	\$205,562																										
20 a. Direct Cost Amount	\$173,329																										
20 b. Indirect Cost Amount	\$32,233																										
21. Authorized Carryover	\$0																										
22. Offset	\$0																										
23. Total Amount of Federal Funds Obligated this budget period	\$205,562																										
24. Total Approved Cost Sharing or Matching, where applicable	\$0																										
25. Total Federal and Non-Federal Approved this Budget Period	\$205,562																										

26. Project Period Start Date 12/01/2020 – End Date 11/30/2022																											
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$478,188																										
<p>30. Remarks Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.</p>																											



SECTION I – AWARD DATA – 5R21AI157929-02

Principal Investigator(s):

Mauricio de Aguiar Martins, PHD

Award e-mailed to: grants@scripps.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$205,562 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to SCRIPPS FLORIDA in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R21AI157929. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Nicole A Guidetti
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Federal Direct Costs	\$173,329
Federal F&A Costs	\$32,233
Approved Budget	\$205,562
Total Amount of Federal Funds Authorized (Federal Share)	\$205,562
TOTAL FEDERAL AWARD AMOUNT	\$205,562
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$205,562

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
2	\$205,562	\$205,562

Fiscal Information:

Payment System Identifier: 1330435954A5
Document Number: RAI157929A
PMS Account Type: P (Subaccount)
Fiscal Year: 2022

IC	CAN	2022
AI	8472297	\$205,562

NIH Administrative Data:

PCC: A22F / **OC:** 41025 / **Released:** Guidetti, Nicole 11/12/2021
Award Processed: 11/15/2021 12:03:38 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R21AI157929-02

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 5R21AI157929-02

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but

non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R21AI157929. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: <http://grants.nih.gov/grants/policy/policy.htm#gps>.

A final expenditure Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 120 days of the period of performance end date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, <http://grants.nih.gov/grants/policy/policy.htm#gps>, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) quarterly cash transaction data. A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e., awards to foreign entities and to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level. If the grantee submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported on the final expenditure FFR and the last cash report to PMS, NIH will close the award at the lower amount. This could be considered a debt or result in disallowed costs.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date. The HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>. This paragraph does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, D42, D43, D71, DP7, G07, G08, G11, K12, K16, K30, P09, P40, P41, P51, R13, R25, R28, R30, R90, RL5, RL9, S10, S14, S15, U13, U14, U41, U42, U45, UC6, UC7, UR2, X01, X02.

Unless an application for competitive renewal is submitted, a Final Research Performance Progress Report (Final RPPR) must also be submitted within 120 days of the period of performance end date. If a competitive renewal application is submitted prior to that date, then an Interim RPPR must be submitted by that date as well. Instructions for preparing an Interim or Final RPPR are at: https://grants.nih.gov/grants/rppr/rppr_instruction_guide.pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the Interim or Final RPPR. *Note that*

